Although the symptoms of mild cerebral infarction are mild, they are prone to recurrence and aggravation if the risk factors are not controlled, so it is especially important to apply medication to treat and prevent recurrence. Anti-platelet aggregation drugs are the most important treatment drugs, mainly including aspirin, clopidogrel, tigretol, cilostazol, etc. These drugs inhibit platelet aggregation and release, so that the local thrombus no longer progresses and expands, and are the basic drugs for the treatment of cerebral infarction, but attention should be paid to the risk of bleeding when taking these drugs, and timely consultation should be made to adjust the medication if gum bleeding, black stool, subcutaneous petechiae, etc. occur. The medication should be adjusted promptly. For cerebral infarction caused by small artery embolism, anticoagulant drugs should be used to prevent re-embolism. The commonly used oral anticoagulant is warfarin, but the INR should be monitored when taking this drug (controlled at 2.0~3.0); there are some new oral anticoagulants such as dabigatran, which do not require INR monitoring; in addition, common heparin is commonly used in the acute stage by intravenous pumping and subcutaneous injection of low molecular heparin. Since patients with cerebral infarction are often accompanied by high-risk factors such as hypertension, diabetes mellitus, hyperlipidemia and hyperhomocysteinemia, these risk factors should be controlled simultaneously and antihypertensive drugs, hypoglycemic drugs and lipid-lowering drugs should be applied under the guidance of doctors. In addition, some traditional Chinese medicines, such as circulation improvement and neurotropic drugs, can also play a supplementary therapeutic role. In conclusion, although mild cerebral infarction has mild symptoms, it is prone to recurrence if risk factors are not controlled, so standardized treatment is needed to address the etiology and the risk factors of cerebrovascular disease present in patients.